These innovative molecules represent a significant leap in the management of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in reducing blood glucose levels. https://junaidflei886673.bluxeblog.com/71286264/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide